In other breast cancer studies with dense chemotherapy with GSCMF, it is believed that dose-dense treatment may partly reflect the inhibition of micrometastasis homing and/or paracrine survival associated with CXCR4 (Epstein, 2004). This evidence concerns the gene CXCR4 and breast carcinoma.